{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T05:07:18Z","timestamp":1692594438377},"reference-count":23,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.3892\/or.2016.5110","type":"journal-article","created":{"date-parts":[[2016,9,20]],"date-time":"2016-09-20T05:33:30Z","timestamp":1474349610000},"page":"2976-2982","source":"Crossref","is-referenced-by-count":8,"title":["Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study"],"prefix":"10.3892","volume":"36","author":[{"given":"Maki","family":"Hagihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyoshi","family":"Iriyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikashi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimihiro","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Takezako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koiti","family":"Inokuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Ohyashiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadahiko","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuji","family":"Kouzai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Sakamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2016,9,20]]},"reference":[{"key":"key20180107221458_b1-or-36-05-2976","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/leu.2008.221","article-title":"Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase","volume":"22","author":"Cortes","year":"2008","journal-title":"Leukemia"},{"key":"key20180107221458_b2-or-36-05-2976","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20180107221458_b3-or-36-05-2976","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/MAJ.0b013e3181ae9227","article-title":"Dasatinib-induced pleural effusions: A lymphatic network disorder?","volume":"338","author":"Goldblatt","year":"2009","journal-title":"Am J Med Sci"},{"key":"key20180107221458_b4-or-36-05-2976","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s12185-010-0565-1","article-title":"Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion","volume":"91","author":"Nagata","year":"2010","journal-title":"Int J Hematol"},{"key":"key20180107221458_b5-or-36-05-2976","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.critrevonc.2013.10.005","article-title":"Dasatinib, large granular lymphocytosis, and pleural effusion: Useful or adverse effect?","volume":"89","author":"Paydas","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Suppl","key":"key20180107221458_b6-or-36-05-2976","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1200\/jco.2011.29.15_suppl.6605","article-title":"Analysis of patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: Management and outcomes","volume":"29","author":"Laneuville","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180107221458_b7-or-36-05-2976","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"key20180107221458_b8-or-36-05-2976","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.23923","article-title":"Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group","volume":"90","author":"Iriyama","year":"2015","journal-title":"Am J Hematol"},{"key":"key20180107221458_b9-or-36-05-2976","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s10147-011-0328-x","article-title":"Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan","volume":"17","author":"Yoshida","year":"2012","journal-title":"Int J Clin Oncol"},{"key":"key20180107221458_b10-or-36-05-2976","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12185-013-1483-9","article-title":"Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia","volume":"99","author":"Kumagai","year":"2014","journal-title":"Int J Hematol"},{"key":"key20180107221458_b11-or-36-05-2976","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"key20180107221458_b12-or-36-05-2976","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12185-011-0921-9","article-title":"Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy","volume":"94","author":"Kim","year":"2011","journal-title":"Int J Hematol"},{"key":"key20180107221458_b13-or-36-05-2976","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hon.2020","article-title":"Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia","volume":"31","author":"Latagliata","year":"2013","journal-title":"Hematol Oncol"},{"key":"key20180107221458_b14-or-36-05-2976","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.leukres.2014.04.004","article-title":"Chronic myeloid leukemia patients who develop grade I\/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion","volume":"38","author":"Eskazan","year":"2014","journal-title":"Leuk Res"},{"key":"key20180107221458_b15-or-36-05-2976","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cncr.24734","article-title":"Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion","volume":"116","author":"Porkka","year":"2010","journal-title":"Cancer"},{"issue":"Suppl","key":"key20180107221458_b16-or-36-05-2976","first-page":"3595","article-title":"Dasatinib pharmacokinetics and exposure-response (E-R): Relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML)","volume":"26","author":"Wang","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180107221458_b17-or-36-05-2976","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180107221458_b18-or-36-05-2976","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis","volume":"141","author":"de Lavallade","year":"2008","journal-title":"Br J Haematol"},{"key":"key20180107221458_b19-or-36-05-2976","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"key":"key20180107221458_b20-or-36-05-2976","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","article-title":"Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy","volume":"116","author":"Kreutzman","year":"2010","journal-title":"Blood"},{"key":"key20180107221458_b21-or-36-05-2976","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.13151","article-title":"Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia","volume":"94","author":"Kim","year":"2009","journal-title":"Haematologica"},{"key":"key20180107221458_b22-or-36-05-2976","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.3109\/10428194.2013.866663","article-title":"Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase","volume":"55","author":"Chuah","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"key20180107221458_b23-or-36-05-2976","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12185-013-1470-1","article-title":"Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up","volume":"99","author":"Fujisawa","year":"2014","journal-title":"Int J Hematol"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2016.5110\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T17:18:27Z","timestamp":1515345507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2016.5110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,20]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,9,20]]},"published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.3892\/or.2016.5110"],"URL":"https:\/\/doi.org\/10.3892\/or.2016.5110","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,20]]}}}